Objective:To explore the adjuvant treatment effect of Bifidobacterium triple live bacteria on children with bronchial asthma complicated with mycoplasma pneumoniae pneumonia. Methods:A total of 136 children with bronchial asthma complicated with mycoplasma pneumoniae pneumonia admitted to the Affiliated Hospital of Jining Medical University from January 2021 to September 2023 were prospectively selected as the study subjects. All the children were given intravenous azithromycin infusion treatment. After the temperature returned to normal, symptoms were reduced, and intravenous infusion treatment was stopped, they were divided into two groups according to random number table method. The control group (68 cases) received montelukast sodium tablets and azithromycin, and the observation group (68 cases) received Bifidobacterium triple live capsule oral treatment on the basis of the control group, both groups continued to use the drug for 2 weeks. The treatment effect, improvement of lung function index and intestinal barrier function index and quality of life assessment were observed in the two groups. Results:The total effective rate in the observation group was higher than that in the control group: 94.12%(64/68) vs. 82.35%(56/68), there was statistical difference ( χ2 = 4.53, P<0.05).After treatment, the forced vital capacity and forced expiratory volume in the first second in both groups were increased, and the observation group were higher than those in the control group: (2.55 ± 0.36) L vs. (2.14 ± 0.31) L, (1.57 ± 0.31)L vs. (1.31 ± 0.25) L, there were statistical differences ( P<0.05). After treatment, the levels of serum endotoxin and diamine oxidase in both groups were decreased, and the observation group were lower than those in the control group: (0.22 ± 0.05) kEU/L vs. (0.38 ± 0.10) kEU/L, (5.80 ± 1.00) μg/L vs.(8.16 ± 2.48) μg/L, there were statistical differences ( P<0.05). After treatment, the scores of symptom-related problems, treatment-related problems, worry-related problems, and communication-related problems in the asthma-specific scale of children's quality of life in both groups increased, and scores in the observation group were higher than those in the control group: (86.73 ± 10.59) scores vs. (80.63 ± 13.53) scores, (87.52 ± 14.73) scores vs. (81.35 ± 17.44) scores, (84.36 ± 11.45) scores vs. (78.85 ± 12.42) scores, (87.62 ± 10.86) scores vs.(83.58 ± 12.53) scores, there were statistical differences ( P<0.05). Conclusions:The application of Bifidobacterium triple live bacteria in the adjuvant treatment of children with bronchial asthma accompanied by mycoplasma pneumoniae pneumonia can significantly improve the clinical efficacy, promote the improvement of lung function and intestinal mucosal barrier function of children, and help improve the prognosis of children.

Objective:To explore the adjuvant treatment effect of Bifidobacterium triple live bacteria on children with bronchial asthma complicated with mycoplasma pneumoniae pneumonia. Methods:A total of 136 children with bronchial asthma complicated with mycoplasma pneumoniae pneumonia admitted to the Affiliated Hospital of Jining Medical University from January 2021 to September 2023 were prospectively selected as the study subjects. All the children were given intravenous azithromycin infusion treatment. After the temperature returned to normal, symptoms were reduced, and intravenous infusion treatment was stopped, they were divided into two groups according to random number table method. The control group (68 cases) received montelukast sodium tablets and azithromycin, and the observation group (68 cases) received Bifidobacterium triple live capsule oral treatment on the basis of the control group, both groups continued to use the drug for 2 weeks. The treatment effect, improvement of lung function index and intestinal barrier function index and quality of life assessment were observed in the two groups. Results:The total effective rate in the observation group was higher than that in the control group: 94.12%(64/68) vs. 82.35%(56/68), there was statistical difference ( χ2 = 4.53, P<0.05).After treatment, the forced vital capacity and forced expiratory volume in the first second in both groups were increased, and the observation group were higher than those in the control group: (2.55 ± 0.36) L vs. (2.14 ± 0.31) L, (1.57 ± 0.31)L vs. (1.31 ± 0.25) L, there were statistical differences ( P<0.05). After treatment, the levels of serum endotoxin and diamine oxidase in both groups were decreased, and the observation group were lower than those in the control group: (0.22 ± 0.05) kEU/L vs. (0.38 ± 0.10) kEU/L, (5.80 ± 1.00) μg/L vs.(8.16 ± 2.48) μg/L, there were statistical differences ( P<0.05). After treatment, the scores of symptom-related problems, treatment-related problems, worry-related problems, and communication-related problems in the asthma-specific scale of children's quality of life in both groups increased, and scores in the observation group were higher than those in the control group: (86.73 ± 10.59) scores vs. (80.63 ± 13.53) scores, (87.52 ± 14.73) scores vs. (81.35 ± 17.44) scores, (84.36 ± 11.45) scores vs. (78.85 ± 12.42) scores, (87.62 ± 10.86) scores vs.(83.58 ± 12.53) scores, there were statistical differences ( P<0.05). Conclusions:The application of Bifidobacterium triple live bacteria in the adjuvant treatment of children with bronchial asthma accompanied by mycoplasma pneumoniae pneumonia can significantly improve the clinical efficacy, promote the improvement of lung function and intestinal mucosal barrier function of children, and help improve the prognosis of children.

Objective To investigate effect of hypertonic-hyperoncotic solution (HHS,namely 4.5 g/ml NaCl plus 6.0 g/ml hydroxyethyl starch) on brain protection in rabbits with pulmonary trauma combined with hemorrhagic shock and the possible mechanism.Methods Thirty New Zealand white rabbits were randomly divided into control group (Group A),lactated Ringer' s solution (LRS) treatment group (Group B) and HHS treatment group (Group C),with 10 rabbits per group.Models of pulmonary trauma with hemorrhagic shock were established in Groups B and C.Later,fluid resuscitation,including LRS at 3-fold the volume of blood loss and HHS at dose of 5 mL/kg,was respectively given for Groups B and C at 60 minutes after shock.Rabbits in each group were sacrificed at 4 hours after resuscitation for brain tissue harvest.Evan blue exudation in the parietal cortex of rabbit brain in each group was observed by fluorescence microscope.Brain water content was weighed and calculated.Neuron apoptosis was tested by TUNEL method.Expressions of Bcl-2 and Bax proteins were detected by Western blot.Resalts Group B showed massive exudation of Evan blue,notable increase of brain water content,large apoptosis of neurons,up-regulation of Bcl-2 and Bax proteins,but a decline of Bcl-2 to Bax ratio,as compared with Group A (P ＜ 0.01).However,Group C showed significant decrease regarding Evan blue exudation,brain water content and apoptotic neurons,and significant increase of ratio of Bcl-2 and Bax,as compared with Group B (P ＜ 0.05).Conclusion HHS improves blood brain barrier,inhibits neuron apoptosis and thus protects brain function.